Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report documented a case of thrombocytopenia and leukopenia linked to the long-term use of itraconazole in a patient with acute myelogenous leukemia.

This study reports that a 15-year-old with trichotillomania showed improvement with aripiprazole treatment, though no consensus on treatment exists in the literature.

This study found no significant association between the MDR1 C3435T polymorphism and methotrexate responsiveness in rheumatoid arthritis patients.

In this study, a patient with over 40 years of Alopecia Universalis achieved complete regrowth of hair on the scalp and eyebrows within less than three years after consistent treatment with oral Tofacitinib, suggesting its potential as a promising therapy for this condition.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study found no significant difference in the overall effectiveness of fractional CO2 laser plus triamcinolone acetonide versus microneedling plus the same treatment for resistant alopecia areata, though initial hair regrowth appeared more frequently in the laser group.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

This study found that ozonated olive oil exhibited antifungal activity against Trichophyton mentagrophytes, comparable to the standard antifungal terbinafine, in an in vivo rat study, suggesting it may serve as an alternative treatment for dermatophytosis.

In this study using zebrafish, four bisbenzylisoquinoline derivatives were found to protect hair cells from aminoglycoside-induced damage without reducing antibiotic efficacy, potentially leading to therapies for patients undergoing such treatments.

This study observed that among Iranian patients with rheumatoid arthritis, methotrexate treatment was discontinued or reduced in nearly half of the cases due to side effects such as nausea, flu-like symptoms, hepatotoxicity, and hair loss, with hepatotoxicity linked to higher doses and longer treatment duration.

In a case-series study, researchers reported significant hair regrowth in Alopecia Areata patients after three months of treatment with a topical preparation called Freezia cream, which was developed by specialized medical professionals and approved by the Iraqi Ministry of Health.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This opinion article explores the possibility of repurposing anticancer drugs, like methotrexate, as antimalarials, highlighting that toxicity might be manageable with appropriate dosing according to Paracelsus' law.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This study reports significant hair regrowth in 11 patients with severe alopecia areata following longstanding treatment with oral tofacitinib and also highlights successful treatment using topical tofacitinib cream in one case.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study found that both oral tranexamic acid and microneedling improve melasma treatment outcomes when added to standard therapy, with microneedling showing a more sustained remission.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.